Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR
Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR is recorded as a service provider in 11 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 11 of 11 trials · Latest update first
Early treatment intensification in patients with high risk Mantle Cell Lymphoma using CAR-T-cell treatment after an abbreviated induction therapy with Rituximab and Ibrutinib and 6 months Ibrutinib maintenance (Arm A) as compared to standard of care induction and maintenance (Arm B)
Sponsor Klinikum Der Universitat Munchen AöR
- Start (EU)
- Latest update
- Estimated end
- Not reported
Safety and tolerability of systemic administration of metformin in patients with Idiopathic Pulmonary Fibrosis (IPF): A randomized, placebo-controlled, double-blind, phase II proof-of-concept study (Met_for_IPF)
Sponsor Philipps-Universitaet Marburg
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
Niraparib vs Niraparib in combination with Bevacizumab in patients with carboplatinum-taxane based chemotherapy in advanced ovarian cancer (A multicentre randomised phase III trial)
Sponsor AGO Research GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
FUTURE platform trial – A phase II platform trial of futibatinib in combination with (chemo)immunotherapy in colorectal cancer and other solid tumor entities
Sponsor Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
Prospective randomized multicenter phase III trial of decitabine and venetoclax administered in combination with all-trans retinoic acid or placebo in patients with acute myeloid leukemia who are ineligible for induction chemotherapy
Sponsor Medical Center - University Of Freiburg
- Start (EU)
- Latest update
- Estimated end
- Not reported
Pembrolizumab in combination with lenvatinib in patients with recurrent, persistent, metastatic or locally advanced vulvar cancer not amenable to curative surgery or radiotherapy
Sponsor AGO Research GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
Window-of-opportunity proof-of-concept, non-randomized, open-label phase II trial of Olaparib given alone (cohort A) or in combination with Durvalumab (cohort B) prior to primary debulking surgery in histologically proven high-grade epithelial ovarian cancer (EOC)
Sponsor AGO Research GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
Bemarituzumab in patients with FGFR2b-positive advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed at least one prior line of palliative chemotherapy - The IKF-AIO Phase IIa BEMARA trial
Sponsor Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
International open-label phase I dose escalation study of dinutuximab beta in combination with vincristine/doxorubicin/cyclophosphamide and ifosfamide/etoposide in pediatric, adolescent, and adult patients with GD2-positive Ewing sarcoma
Sponsor GPOH gGmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
Tezepelumab (Anti-TSLP-mab) in progressive pulmonary fibrosis interstitial lung disease with evidence of eosinophilia - A prospective two-armed, phase II clinical multicentre randomized, placebo-controlled (2:1), blinded with open-label extension trial (TEFIBEOS)
Sponsor Philipps-Universitaet Marburg
- Start (EU)
- Latest update
- Estimated end
- Not reported
Allogeneic stem cell transplantation vs. conventional therapy as salvage therapy for relapsed / progressive patients with multiple myeloma after a first-line therapy
Sponsor University Medical Center Hamburg-Eppendorf
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR?
The 2026-10-09 snapshot links Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR to 11 distinct CTIS trials. Recorded services include Laboratory services, Medicinal product management, Clinical monitoring, Data management, among 12 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR?
The most frequently recorded therapeutic areas are Solid Tumor Oncology, Gynecology, Haematological Malignancies, Gastroenterology. Recorded phases include Phase 2, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR conducted?
The linked trials record locations in 9 countries, including Germany, Czechia, Spain, Austria, Belgium. These are trial locations, not confirmed office locations or countries where Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR delivered services.
What can this page tell me about Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR's trial experience?
Browse 11 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR